India Gene Therapy Market Research Report By Therapeutic Area (Oncology, Genetic Disorders, Infectious Diseases, Cardiovascular Diseases, Neurological Disorders), By Technology (Viral Vectors, CRISPR, Gene Editing, RNA Therapy, Non-Viral Methods), By Application (Research, Clinical, Commercial) and By Route of Administration (Intravenous, Intramuscular, Intradermal, Intrathecal, Oral)- Forecast to 2035

India Gene Therapy Market Overview

As per MRFR analysis, the India Gene Therapy Market Size was estimated at 258 (USD Million) in 2024.The India Gene Therapy Market Industry is expected to grow from 290.8(USD Million) in 2025 to 1,040 (USD Million) by 2035. The India Gene Therapy Market CAGR (growth rate) is expected to be around 12.283% during the forecast period (2025 - 2035)

Key India Gene Therapy Market Trends Highlighted

The India gene therapy market is witnessing significant market trends driven by advancements in biotechnology and increased support from the government. The Indian government is actively promoting research and development in gene therapy, recognizing its potential to address various genetic disorders that are prevalent in the country. Initiatives like "Make in India" and the establishment of regulatory frameworks to streamline approvals highlight the commitment to fostering a conducive environment for gene therapy innovations. 

Opportunities to be explored include collaboration between domestic and international research institutions, which can enhance the development of new therapies tailored to the Indian population.As genetic disorders, such as thalassemia and sickle cell anemia, are widespread in India, there is a pressing need for effective treatment options. Additionally, the growing awareness and acceptance of gene therapy among healthcare professionals and patients present further avenues for market expansion. Trends in recent times show a surge in clinical trials and research focused on personalized medicine approaches. 

Companies are increasingly developing targeted therapies that are specific to genetic mutations prevalent in the Indian demographic. Moreover, advancements in CRISPR technology and the associated reduction in costs for gene editing techniques have encouraged more players to enter the market.The integration of digital health solutions with gene therapy is also on the rise, making it easier for researchers and clinicians to track patient outcomes and enhance treatment effectiveness. Overall, these trends signify a dynamic evolution within the India gene therapy market, presenting a promising landscape for future growth and innovation.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

India Gene Therapy Market Drivers

Increasing Genetic Disorders and Rare Diseases Prevalence

In India, the rise in genetic disorders and rare diseases has been a significant catalyst for the growth of the India Gene Therapy Market Industry. It is reported that around 6% to 8% of the Indian population suffers from some form of genetic disorder, which translates to over 70 million individuals affected by conditions like hemophilia, thalassemia, and muscular dystrophy. The Government of India has recognized this challenge and has initiated several programs aimed at diagnosing and treating these diseases through advanced gene therapy techniques.

Organizations such as the Indian Council of Medical Research (ICMR) have stressed the necessity of developing innovative treatment methods, further paving the way for growth in the gene therapy sector. The emerging biotechnology companies in India are rapidly entering the market, emphasizing the need for cutting-edge solutions to address these pressing health issues. This trend indicates that the demand for gene therapy solutions will continue to rise as more patients seek access to effective treatment options.

Government Initiatives and Regulatory Support

The Indian government is increasingly supportive of biotechnology and gene therapy initiatives, providing a conducive regulatory environment that fosters innovation. Policies such as the National Biotechnology Development Strategy aim to enhance the bio-economy of India, pushing in the direction of advanced therapies including gene therapy. For instance, approval processes have been expedited for clinical trials relating to gene therapy, which facilitates quicker market entry of new treatments.

The Department of Biotechnology (DBT) is actively supporting biotechnology research and development (R&D), including gene therapy for rare diseases, facilitating advancements and receiving government funding. This initiative positions India on the world map of gene therapy and invites investments while prompting domestic pharmaceutical companies to develop novel treatment alternatives.

Technological Advancements in Gene Editing

Technological advancements, particularly in gene editing technologies like CRISPR-Cas9, are playing a pivotal role in advancing the India Gene Therapy Market Industry. The expansion of these technologies has led to groundbreaking research and development, enabling scientists and researchers in India to address complex genetic issues more effectively. According to the Department of Biotechnology, Indian scientists have published over 5,000 research papers in genetic and molecular research the last decade, evidencing the rapid growth of this sector.

These advancements have not only improved the efficacy of gene therapies but have also reduced costs significantly, making therapies more accessible and appealing to the Indian populace, which is critical for addressing a large patient base suffering from hereditary conditions.

Increased Investment and Collaborations in Gene Therapy R&D

There is a noticeable increase in investments and collaborations in the field of gene therapy within India, driven by both public and private sectors. Major pharmaceutical companies and biotechnology firms are recognizing the potential of gene therapies and allocating significant funds toward Research and Development initiatives. The Biocon Academy, for example, has launched programs to foster collaboration between industry and academia, enhancing training and research capabilities in gene therapy.

Recent funding reports indicate that over 100 biotech startups focused on gene therapy have emerged in India within the past five years, with investments surpassing billions of dollars. This emboldens the landscape for innovation and gives rise to new therapies that can effectively mitigate genetic disorders, thereby enhancing the overall growth and future prospects of the India Gene Therapy Market.

India Gene Therapy Market Segment Insights

Gene Therapy Market Therapeutic Area Insights

The India Gene Therapy Market within the Therapeutic Area segment is experiencing substantial growth as it harnesses innovative technologies to address a wide range of diseases. With the overall industry expected to witness remarkable expansion, the focus on various conditions such as Oncology, Genetic Disorders, Infectious Diseases, Cardiovascular Diseases, and Neurological Disorders is becoming increasingly significant. Oncology, in particular, leads the way as researchers explore targeted approaches in gene manipulation to treat cancerous cells, offering hope for more effective therapies and personalized medicine.

Genetic Disorders, affecting millions in India, highlight the potential for gene therapy to correct underlying genetic defects, providing a long-term solution rather than just symptomatic relief. Infectious Diseases also play a crucial role, especially as the recent global pandemic has underscored the necessity for advanced therapeutic strategies to combat viral infections, where gene therapies could pave the way for innovative vaccines and treatments. Cardiovascular Diseases, one of the leading causes of mortality in India, benefit from gene therapy’s ability to potentially restore normal function to genetic anomalies associated with heart conditions.

Likewise, Neurological Disorders represent a market with significant unmet needs, where gene therapy may offer breakthroughs in treating conditions like Alzheimer’s and Parkinson’s, are increasing in prevalence among the aging population. Overall, the diversification within the Therapeutic Area segment of the India Gene Therapy Market showcases a dynamic landscape with vast opportunities for healthcare advancement, driven by increasing research initiatives, government support for biotechnology, and a growing recognition of the benefits of gene-based therapies.

With improved Healthcare Infrastructure and favorable policies, India is positioning itself as a major player in the gene therapy arena, enhancing treatment paradigms across various therapeutic areas and potentially transforming outcomes for patients suffering from these challenging health conditions.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Gene Therapy Market Technology Insights

The Technology segment of the India Gene Therapy Market includes various innovative approaches, each contributing significantly to the advancement of therapeutic solutions. Viral Vectors are pivotal in delivering genetic material into cells efficiently, making them a popular choice among researchers and developers. CRISPR technology stands out due to its precision and versatility in gene editing, enabling tailored approaches for various genetic disorders. Gene Editing methodologies are expanding their applicability across different diseases, therefore holding a considerable share of the market due to their potential for targeted treatments.

RNA Therapy offers promise in addressing diseases by directly modifying RNA, presenting new avenues for treating conditions that were previously resistant to traditional methods. Non-Viral Methods, though often less prevalent, enhance safety and reduce the risk associated with gene delivery mechanisms, thereby appealing to a broader range of applications. This diverse array of technologies is crucial as the India Gene Therapy Market continues to evolve, driven by the increasing prevalence of genetic disorders, advancements in Research and Development, and supportive government initiatives aimed at boosting the biotechnology sector.

The combination of these technologies fosters innovation and creates opportunities for breakthroughs in treatment strategies within the Indian healthcare landscape.

Gene Therapy Market Application Insights

The Application segment of the India Gene Therapy Market plays a crucial role in advancing medical science and improving patient outcomes. This segment can be broken down into various focuses, including Research, Clinical, and Commercial applications, each contributing significantly to the overall growth of the industry. Research applications are essential as they facilitate the development of gene therapies and the exploration of genetic diseases, driving innovation and discovery in this field. In the Clinical application area, it emphasizes the translation of these innovative therapies into effective treatments for patients, showcasing the potential to cure diseases that were previously considered untreatable.

The Commercial aspect addresses the need for these therapies to reach the market successfully, ensuring accessibility for patients while driving revenue growth for companies involved. With India rapidly becoming a hub for biomedical research and innovation, the India Gene Therapy Market is expected to witness an increase, bolstered by supportive government initiatives and funding. The market growth also benefits from rising incidences of genetic disorders and a growing emphasis on personalized medicine in the healthcare system. As the country invests more in advanced therapies and infrastructure, the Application segment will become increasingly important in shaping the future landscape of healthcare in India.

Gene Therapy Market Route of Administration Insights

The Route of Administration segment plays a crucial role in the overall dynamics of the India Gene Therapy Market as it significantly influences the efficacy, safety, and convenience of therapeutic treatments. Within this segment, several administration methods are emerging, including Intravenous, Intramuscular, Intradermal, Intrathecal, and Oral. Intravenous administration is often seen as advantageous due to its direct infusion into the bloodstream, offering rapid therapeutic effects. In contrast, Intramuscular and Intradermal routes are gaining traction for localized treatment, potentially reducing systemic side effects.Intrathecal administration is vital for targeting central nervous system disorders, as it allows for direct delivery to the cerebrospinal fluid. 

Meanwhile, Oral administration may provide a non-invasive alternative, appealing to patients' preferences for ease of use. With an increasing prevalence of genetic disorders in India, the demand for diverse and effective routes of administration is on the rise. The growing emphasis on Research and Development efforts in the region is likely to propel innovations in administration techniques and enhance patient outcomes.Overall, understanding the significance of these routes can unlock substantial opportunities within the India Gene Therapy Market, fueling its future growth.

India Gene Therapy Market Key Players and Competitive Insights

The India Gene Therapy Market is experiencing notable advancements driven by the increasing prevalence of genetic disorders, the demand for innovative therapies, and substantial investments in biopharmaceutical research and development. Gene therapy, which focuses on correcting defective genes responsible for disease development, is emerging as a potential game-changer in addressing unmet medical needs in the country. This market is characterized by a dynamic landscape where various companies strive to establish their foothold by innovating and offering targeted solutions. 

The competition is primarily influenced by strategic partnerships, collaborations with research institutions, investments in clinical trials, and the regulatory environment that governs the approval process for new therapies. Understanding the competitive insights of this market is crucial for stakeholders to navigate the complexities and identify potential growth opportunities.BristolMyers Squibb has a significant presence in the India Gene Therapy Market, leveraging its global experience and comprehensive portfolio of innovative therapies. The company's research focus on rare genetic disorders and its strong commitment to advancing gene therapies positioned it as a formidable player within the competitive landscape. 

BristolMyers Squibb has excelled in executing clinical trials and establishing partnerships with local healthcare institutions, further strengthening its outreach and market penetration in India. The company is recognized for its robust supply chain, ensuring that its gene therapies are accessible to patients in need. This focus on accessibility, combined with a dedication to patient-centric solutions, has enhanced its reputation and competitive edge in the industry.Amgen is another prominent entity in the India Gene Therapy Market, known for its pioneering work in biotechnology and gene therapy solutions. The company is committed to advancing innovative therapies for serious conditions, with a notable emphasis on rare diseases and metabolic disorders. 

Amgen's strengths lie in its well-established research and development capabilities, which enable it to bring breakthrough therapies to market effectively. Its strategic presence in India is bolstered by key products that cater specifically to local needs, addressing regional healthcare challenges. Furthermore, Amgen's investment in partnerships with local research institutions has facilitated the acceleration of clinical trials and data generation. The company has also explored strategic mergers and acquisitions to enhance its capabilities and expand its portfolio in the gene therapy domain, thereby solidifying its market presence and driving future growth initiatives tailored to the unique needs of the Indian populace.

Key Companies in the India Gene Therapy Market Include

• BristolMyers Squibb


• Amgen


• Bluebird Bio


• CureVac


• Genzyme


• Medigene


• Regeneron Pharmaceuticals


• Gilead Sciences


• Roche


• Sarepta Therapeutics


• Intellia Therapeutics


• Spark Therapeutics


• Regenxbio


• AbbVie


• Novartis

India Gene Therapy Market Industry Developments

Recent developments in the India Gene Therapy Market have illustrated a growing interest and investment in innovative treatments. Notably, companies like Bristol-Myers Squibb and Amgen are expanding their presence, with ongoing Research and Development initiatives to address genetic disorders prevalent in India. In terms of mergers and acquisitions, there are no significant updates reported this year related to the specified companies. 

However, in the past few years, Gilead Sciences launched its Yescarta therapy in India in November 2021, enhancing the availability of CAR T-cell therapies. Additionally, Novartis has been actively working on advancing the accessibility of its Zolgensma gene therapy, which aims to treat spinal muscular atrophy, a genetic disease affecting infants, demonstrating commitment to tap into the Indian market. 

Recently, the market valuation for gene therapy has seen substantial growth, driven by increasing awareness and demand for personalized medicine. Furthermore, India’s regulatory body has been working on frameworks to facilitate gene therapy approvals, which should further boost innovation and market expansion. The Indian government endorses advanced biotechnological research, positioning the nation as a vital hub for gene therapy advancements in Asia.

India Gene Therapy Market Segmentation Insights

Gene Therapy Market Therapeutic Area Outlook

• Oncology


• Genetic Disorders


• Infectious Diseases


• Cardiovascular Diseases


• Neurological Disorders

Gene Therapy Market Technology Outlook

• Viral Vectors


• CRISPR


• Gene Editing


• RNA Therapy


• Non-Viral Methods

Gene Therapy Market Application Outlook

• Research


• Clinical


• Commercial

Gene Therapy Market Route of Administration Outlook

• Intravenous


• Intramuscular


• Intradermal


• Intrathecal


• Oral

Report Attribute/Metric Source:	Details
MARKET SIZE 2023	258.0(USD Million)
MARKET SIZE 2024	290.8(USD Million)
MARKET SIZE 2035	1040.0(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR)	12.283% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
MARKET FORECAST PERIOD	2025 - 2035
HISTORICAL DATA	2019 - 2024
MARKET FORECAST UNITS	USD Million
KEY COMPANIES PROFILED	BristolMyers Squibb, Amgen, Bluebird Bio, CureVac, Genzyme, Medigene, Regeneron Pharmaceuticals, Gilead Sciences, Roche, Sarepta Therapeutics, Intellia Therapeutics, Spark Therapeutics, Regenxbio, AbbVie, Novartis
SEGMENTS COVERED	Therapeutic Area, Technology, Application, Route of Administration
KEY MARKET OPPORTUNITIES	Rising prevalence of genetic disorders, Increasing R&D funding, Government support and incentives, Advanced manufacturing capabilities, Growing awareness and education programs
KEY MARKET DYNAMICS	Rising prevalence of genetic disorders, Increasing investments in R&D, Supportive regulatory frameworks, Growing awareness and acceptance, Expanding healthcare infrastructure
COUNTRIES COVERED	India